Theranostics Health

The deals bring together Avant's ovarian cancer diagnostic, Amarantus' multiple sclerosis and Alzheimer's disease assays, and Theranostics' CLIA lab.

The deal brings together three firms that have struggled to ramp their test businesses in hopes that the combined outfit will be better positioned to succeed.

Avant and Amarantus, which agreed to merge in January, have now signed a deal to acquire Theranostics Health and its CLIA-certified laboratory.

The assays, which the company plans to launch at the end of the month, will use RPPA measurements of cancer signaling pathways to guide patient treatment.

Avera Health will offer the TheraLink Assay to its employees and conduct studies to establish the clinical utility of the proteomic panel.

The marker has the potential to improve upon existing markers like HER2 and HR status while also expanding the population of patients considered for neratinib treatment.

Theranostics Health has appointed Luis Gutierrez president and CEO. Former CEO Glenn Hoke will remain with the company as executive vice president and COO.

Theranostics Health has appointed Luis Gutierrez president and CEO. Former CEO Glenn Hoke will remain with the company as executive VP and COO.

George Mason University researcher Emanuel Petricoin and venture capitalist Dendy Young have partnered on a concierge medicine company aimed at bringing personalized cancer treatment to the community hospital setting.

Led by Gordon Mills, chair of systems biology at the University of Texas MD Anderson Cancer Center, a group of researchers is developing a database containing proteomic characterizations of thousands of cancer patient samples and cell lines.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.